




cambridge.org/cty

Faiz Rasool¹ , Amna Zafer Qureshi¹, Asim Khan², Tehmina Kazmi³ and Salman Ahmad Shah¹

Original Article

Cite this article: Rasool F, Qureshi AZ, Khan A, Kazmi T, and Shah SA (2024) Role of BT shunt in tetralogy of Fallot. *Cardiology in the Young* **34**: 2445–2448. doi: [10.1017/S1047951124025836](https://doi.org/10.1017/S1047951124025836)

Received: 25 May 2024

Revised: 31 May 2024

Accepted: 31 May 2024

First published online: 10 October 2024

Keywords:

BT shunt; tetralogy of Fallot; PDA stent

Corresponding author:

Faiz Rasool;

Email: faiz03009454461@gmail.com

¹Children Hospital Lahore, Lahore, Punjab, Pakistan; ²The Children's Hospital and University of Child Health Sciences, Lahore, Punjab, Pakistan and ³Department of Paediatric Cardiology, The Children's Hospital University of Child Health Sciences, Lahore, Punjab, Pakistan

Abstract

Introduction: Modified Blalock-Taussig shunt (BT shunt) is a palliative operation used for cyanotic heart diseases with decreased pulmonary blood supply. The definitive management of tetralogy of Fallot (TOF) is total corrective surgery, but these patients can be palliated with BT shunt. In the modern world, the BT shunt is getting out of favour in patients with TOF. In this article, we will share our 5-year experience at our institute, which also shows a decreasing trend. **Patients and methods:** It is a retrospective study. Files of all the patients admitted in our department from January 2019 to December 2023 were reviewed. Age, weight, hospital stay, inotropic support duration, mechanical ventilation duration, and outcomes were studied. **Results:** From January 2019 to December 2023, 173 patients underwent BT shunt for TOF. The mean age was 31 months, and the mean weight was 9.3 kg. The overall mortality for BT shunt was 15% after BT shunt. Hypercyanotic spell not controlled by medical management was the most common indication for BT shunt in our setup. Most of the patients with hypercyanotic spells were also candidates for total correction but due to the emergency, BT shunt was performed. **Conclusion:** The role of BT shunt in patients with TOF is decreasing due to PDA/RVOT stenting, it is likely that the BT shunt in TOF will become a thing of the past in the future even in developing countries like ours.

Introduction

Modified Blalock-Taussig shunt (BT shunt) is a palliative operation used for cyanotic heart diseases in with decreases pulmonary blood supply. The first BT shunt was performed at Johns Hopkins Hospital in 1944 by collaborative work of three individuals: the paediatric cardiologist Dr Helen Taussig, the cardiac surgeon Dr Alfred Blalock, and Mr. Vivien Thomas, a laboratory assistant.¹ The original technique has been modified, which utilises an interposition polytetrafluoroethylene (PTFE) graft to make a systemic to pulmonary shunt without transecting the subclavian artery.² The definitive management of tetralogy of Fallot (TOF) is total corrective surgery, but these patients can be managed with BT shunt. The aim is to enhance the growth of pulmonary arteries by increasing pulmonary perfusion.³

With the advancement in interventional cardiology, palliative interventions like right ventricular outflow tract stent,⁴ balloon pulmonary valvotomy,⁵ and PDA (patent ductus arteriosus) stenting,⁶ the role of BT shunt in TOF is decreasing. In Figure 1, we have shown the latest algorithm for the management of TOF, which does not have BT shunt in it.⁷

In this article, we will share our 5-year experience at our institute.

Patients and methods**Settings**

Children Hospital Lahore/University of Child Health Sciences.

Duration

Five years (January 2019–December 2023). It is a retrospective observational study. Files of all the patients admitted in our department from January 2019 to December 2023 were reviewed. Age, weight, hospital stay, inotropic support duration, mechanical ventilation duration, and outcome were studied. In each year, a number of patients were noted, the indications for BT shunt were noted, the site of incision (sternotomy/thoracotomy) was noted, and major outcomes were described in percentages. The age, weight, and other characteristics were described in mean with range.

Results

As shown in Figure 2, from January 2019 to December 2023, 595 patients underwent total correction, while 173 patients underwent BT shunt.




Figure 1. Current management algorithm for TOF.




Figure 2. Five years data of BT shunt in TOF.

The mean age was 31 months, and the mean weight was 9.3 kg. The overall mortality for BT shunt was 15% after BT shunt. Table 1 shows the patient characteristics. Table 2 shows indications for BT shunt.

Hypercyanotic spell not controlled by medical management was the most common indication for BT shunt in our setup. About 12 patients required cardiopulmonary bypass for BT shunt. Most of them were those with disconnected pulmonary arteries.

About 27 (15%) patients died during hospital stay. The most common cause of death was shunt blockage. A few patients died of pulmonary overflooding and left ventricular dysfunction. A 5 mm

PTFE graft was used in 138 patients, while 4 mm in 6 mm grafts were used in others. Only two patients received a 3.5 mm shunt.

Most of the surgeons in our institute prefer left thoracotomy for BT shunt, but some routinely do median sternotomy for BT shunt.

Discussion

While the modern world is moving towards interventions like PDA stenting or right ventricle outflow tract stenting, the role of BT shunt in developing countries like ours is also on the decline as shown in Figure 2. While PDA stenting is becoming more common

Table 1. Characteristics of the patients

N	173	
Mean age	31 months	2–121 months
Mean weight	9.2 kg	3.5–25 kg
Mean hospital stay	8 days	5–30 days
Mean duration of mechanical ventilation	20 hours	6–48 hours
Duration of inotropic support	27 hours	8–29 hours
Left thoracotomy	128	
Median sternotomy	45	
Cardiopulmonary bypass	12	

Table 2. Indications of BT shunt

Cyanotic spells	135
Small pulmonary arteries	23
Disconnected pulmonary arteries	6
Contraindications to CPB	9

CPB = cardiopulmonary bypass.

in developed countries, we are moving towards total correction of TOF in earlier age groups. Now, we are doing total correction at a lower age. Figure 3 shows the decline in the mean age at the time of total correction over the last 7 years. While in the modern world, it is rare to see unrepaired patient with TOF beyond the age of 6 months, in our setup, where there are large numbers of patients waiting for surgery, elective repair of TOF before the age of 6 months is probably not possible in the near future.

In our institute, till 2015, the trend was to go for BT shunt in any patient with TOF who has weight less than 10 kg. With the improvement in intraoperative and post-operative care, we are now doing total correction in TOF patients with weight as low as 5 kg.

The mortality rate of BT shunt in TOF is 4–8%,⁸ while those who need cardiopulmonary bypass for shunt placement have a higher mortality rate especially in neonates.^{9,10} In our study, the mortality rate for BT shunt placement was 15%, which is higher than the international standards. This can be attributed to poor post-operative care in ICU. Most of the deaths occurred in our ICU within 48 hours post-operatively. Shunt blockage was the most common reason for the death. In a few patients, ventricular dysfunction was aggravated by the BT shunt resulting in death. Our results are comparable to a study by Ryandi,¹¹ which had a mortality rate of 12–14.5%.

The thoracotomy approach was used more often than sternotomy for the BT shunt procedure at our centre. This approach is thought to be accessible, faster, and safer, but a study in Boston revealed that thoracotomy had higher chances of failure as compared to sternotomy.¹³ One of the life-threatening risk is phrenic nerve paralysis, with chances as high as 23.8% in patients who undergo this procedure through thoracotomy.¹⁴ In our study, there was not a single incidence of phrenic nerve injury during BT shunt placement.

PDA stenting is replacing BT shunt in developed countries, which has shown promising results.¹⁵ Tseng et al. in their meta-analysis showed the superiority of PDA stent over BT shunt in terms of better haemodynamics and hospital stay.¹⁶ Sheeth et al.¹⁷ in their study demonstrated better and smoother ICU stay with ductal stenting. Nesser¹⁸ and Al Kindi¹⁹ in their studies highlighted the importance of PDA stenting as the first option in patients with PDA-dependent pulmonary circulation.

In our institute, PDA stenting is rapidly being developed. With primary repair being done at earlier age and development of PDA stenting programme, the role of BT shunt in TOF will soon be a history.

Conclusion

While the role of BT shunt in patients with TOF is decreasing due to PDA/RVOT stenting, it is likely that the BT shunt in TOF will become a thing of the past in the future even in developing countries like ours.




Figure 3. Decreasing mean age for total correction for tetralogy of Fallot.

References

1. Mainwaring RD, Mainwaring S. The retirement years of Doctor Helen B. Taussig: an intersection of art and medicine. *Cardiol Young* 2023; 34: 1–14.
2. Yuan SM, Shinfeld A, Raanani E. The Blalock-Taussig shunt. *J Card Surg* 2009; 24: 101–108.
3. Starr JP. Tetralogy of Fallot: yesterday and today. *World J Surg* 2010; 34: 658–668.
4. Li D, Zhao T, Hu S, Zhang W, Wu Z, Liu J. Comparison between the modified Blalock-Taussig shunt and right ventricular outflow tract stent in the palliative treatment for tetralogy of Fallot. *Zhong Nan Da Xue Xue Bao Yi Xue Ban* 2023; 48: 1325–1332. DOI: [10.11817/j.issn.1672-7347.2023.230105](https://doi.org/10.11817/j.issn.1672-7347.2023.230105).
5. Remadevi KS, Vaidyanathan B, Francis E, Kannan BR, Kumar RK. Balloon pulmonary valvotomy as interim palliation for symptomatic young infants with tetralogy of fallot. *Ann Pediatr Cardiol* 2008; 1: 2–7. DOI: [10.4103/0974-20694.1049](https://doi.org/10.4103/0974-20694.1049).
6. Ilyas S, Rehman Y, Hussain I, Khan A, Ahmed T, Akbar A. Emergency department presentation and outcome of children with cyanotic congenital heart diseases. *Cureus* 2021; 13: e17960. DOI: [10.7759/cureus.17960](https://doi.org/10.7759/cureus.17960).
7. Moorjani N. Tetralogy of Fallot, Key Questions in Congenital Cardiac Surgery. In: Moorjani N (ed). TFM Publications, 2022: 697.
8. Singh SP, Chauhan S, Choudhury M *et al.* Modified Blalock Taussig shunt: comparison between neonates, infants and older children. *Ann Card Anaesth* 2014; 17: 191–197.
9. Petrucci O, Brien O', Jacobs SM *et al.* Risk factors for mortality and morbidity after the neonatal Blalock-Taussig shunt procedure. *Ann Thorac Surg*. 2011; 92: 642–651.
10. Ashraf SS, Tian Y, Zacharrias S, Cowan D, Martin P, Watterson K. Effects of cardiopulmonary bypass on neonatal and paediatric inflammatory profiles. *Eur J Cardiothorac Surg*. 1997; 12: 862–868.
11. Riyandi M, Lilyasari O, Juzar DA, Rahmat B. Age criteria as operative mortality predictor after modified Blalock-Taussig shunt. *Indones J Cardiol*. 2019; 40: 216–221. DOI: [10.30701/ijc.v40i1.763](https://doi.org/10.30701/ijc.v40i1.763).
12. Odum J, Portzky M, Zurakowski D *et al.* Sternotomy approach for the modified Blalock-Taussig shunt. *Circulation*. 1995; 92: 256–261. DOI: [10.1161/01.CIR.92.9.256](https://doi.org/10.1161/01.CIR.92.9.256).
13. Talwar S, Kumar MV, Muthukkumaran S, Airan B. Is sternotomy superior to thoracotomy for modified Blalock-Taussig shunt? *Interact Cardiovasc Thorac Surg*. 2014; 18: 371–375. DOI: [10.1093/icvts/ivt513](https://doi.org/10.1093/icvts/ivt513).
14. Akay TH, Ozkan S, Gultekin B *et al.* Diaphragmatic paralysis after cardiac surgery in children: incidence, prognosis and surgical management. *Pediatr Surg Int*. 2006; 22: 341–346. DOI: [10.1007/s00383-006-1663-2](https://doi.org/10.1007/s00383-006-1663-2).
15. Glatz AC, Petit CJ, Goldstein BH *et al.* Comparison between patent ductus arteriosus stent and modified Blalock-Taussig shunt as palliation for infants with ductal-dependent pulmonary blood flow: insights from the congenital catheterization research collaborative. *Circulation* 2018; 137: 589–601.
16. Tseng SY, Truong VT, Peck D *et al.* Patent ductus arteriosus stent versus surgical aortopulmonary shunt for initial palliation of cyanotic congenital heart disease with ductal-dependent pulmonary blood flow: a systematic review and meta-analysis. *J Am Heart Assoc* 2022; 11: e024721. DOI: [10.1161/JAHA.121.024721](https://doi.org/10.1161/JAHA.121.024721).
17. Shaath GA, Jijeh AM, Fararjeh M *et al.* What could be better for children with duct dependent pulmonary circulation? *J Saudi Heart Assoc* 2021; 33: 306–312. DOI: [10.37616/2212-5043.1274](https://doi.org/10.37616/2212-5043.1274).
18. Nasser BA, Abdulrahman M, Qwae AAL, Alakfash A, Mohamad T, Kabbani MS. Impact of stent of ductus arteriosus and modified Blalock-Taussig shunt on pulmonary arteries growth and second-stage surgery in infants with ductus-dependent pulmonary circulation. *J Saudi Heart Assoc* 2020; 32: 86–92. DOI: [10.37616/2212-5043.1014](https://doi.org/10.37616/2212-5043.1014).
19. Al Kindi H, Al Harthi H, Al Balushi A *et al.* Blalock-Taussig shunt versus ductal stenting as palliation for duct-dependent pulmonary circulation. *Sultan Qaboos Univ Med J* 2023; 23: 10–15. DOI: [10.18295/squmj.12.2023.073](https://doi.org/10.18295/squmj.12.2023.073).